Safety and Efficacy of Xyrem Oral Solution (Sodium Oxybate) Compared With Placebo in Narcoleptic Patients
NCT ID: NCT00049803
Last Updated: 2005-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
200 participants
INTERVENTIONAL
2000-12-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
sodium oxybate
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Willing \& able to complete entire trial as described in protocol.
* 16 years of age or older.
* Have a history and presenting symptoms of excessive daytime sleepiness.
* Have a history of cataplexy localizable to a specific muscle group(s) or part(s) of body during which the patient is lucid (not experiencing an inadvertent nap or micro sleep).
* Have valid PSG \& MSLT scores (collected during an overnight test) within last five years and a current diagnosis of narcolepsy according to the following criteria established by the American Sleep Disorders Association: (1) Recurrent daytime naps or lapses into sleep occur almost daily for at least 3 months; (2) Sudden bilateral loss of postural muscle tone occurs in association with intense emotion (cataplexy); (3) Polysomnography demonstrates one or more of the following: (a) Sleep latency less than 10 minutes; (b) REM sleep latency less than 20 minutes; (c) An MSLT that demonstrates a mean sleep latency of less than 5 minutes; (d) Two or more sleep-onset REM periods
* Females who are surgically sterile, two years post-menopausal, or if of child-bearing potential, using a medically accepted method of birth control and agree to continue use of this method for the duration of the trial.
* In the opinion of the investigator, have adequate support for the duration of trial to include transportation to and from trial site. In addition, if in the investigator's assessment it is clinically indicated, the patient is willing to not operate a car or heavy machinery for the duration of the trial or for as long as the investigator deems clinically indicated.
Exclusion Criteria
* Have taken any investigational therapy within 30-day period prior to initial screening visit for this trial.
* Patients taking fluoxetine (Prozac).
* Have been diagnosed with sleep apnea syndrome, defined as an Apnea Index \> 10 per hour or an Apnea Hypopnea Index greater than 15 per hour, or have any other cause of daytime sleepiness, and have any other disorder(s) that can be considered a primary cause of excessive daytime sleepiness.
* Taking hypnotics, tranquilizers, antihistamines (except for non-sedating antihistamines), benzodiazepines or clonidine at the start of the baseline period. Patients taking anticonvulsants are not eligible to participate even if willing to washout anticonvulsants for the trial.
* Experiencing unstable cardiovascular, endocrine, neoplastic (excluding localized basal cell carcinoma), gastrointestinal, hematologic, hepatic, immunologic, metabolic, neurological (other than narcolepsy/cataplexy), pulmonary, and/or renal disease which would place the patient at risk during the trial or compromise objectives outlined in the protocol.
* Have psychiatric disorders, major affective or psychotic disorders, or other problems that, in the investigator's opinion, would preclude the patient's participation and completion of this trial or compromise reliable representation of subjective symptoms.
* Have current or recent (within one year) history of a substance use disorder including alcohol abuse as defined by DSM-IV.
* Serum creatinine greater than 2.0 mg/dL, abnormal liver function tests (SGOT \[AST\] or SGPT \[ALT\] more than twice the upper limit of normal), or elevated serum bilirubin (more than 1.5 times upper limit of normal), or pre-trial ECG results demonstrating clinically significant arrhythmias, greater than a first degree AV block or a history of myocardial infarction within last six months.
* Have an occupation that requires variable shift work or routine night shift.
* Have a clinically significant history of seizure disorder, a history of clinically significant head trauma (i.e., concussion resulting in clinically significant loss of consciousness) or past invasive intracranial surgery, and are taking anticonvulsant medications.
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orphan Medical
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
William Houghton, MD
Role: STUDY_CHAIR
Orphan Medical
Harry N Cook, MBA, RPh
Role: STUDY_DIRECTOR
Orphan Medical
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sleep Disorders Center of Alabama, Inc.
Birmingham, Alabama, United States
Pacific Sleep Medicine Services
La Jolla, California, United States
Stanford Sleep Disorders Clinic
Stanford, California, United States
St. Petersburg Sleep Disorders Center
St. Petersburg, Florida, United States
Sleep Disorders Center of Georgia
Atlanta, Georgia, United States
Sleep Disorders Center--Division of Neurology
Evanston, Illinois, United States
Peoria Pulmonary Associates, Ltd.
Peoria, Illinois, United States
The Center for Sleep and Wake Disorders/Midwest Neurology
Danville, Indiana, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Fort Wayne Neurological Center
Fort Wayne, Indiana, United States
Chest Medicine Associates DBA/Sleep Medicine Specialists
Louisville, Kentucky, United States
LSU Health Science Center
Shreveport, Louisiana, United States
Center for Sleep and Wake Disorders
Chevy Chase, Maryland, United States
Center for Sleep Diagnostics
Newton, Massachusetts, United States
Department of Neurology
Worcester, Massachusetts, United States
Washington University -- Sleep Medicine Center
St Louis, Missouri, United States
Sleep/Wake Center 7N2 -- Bellevue Hospital Center
New York, New York, United States
The Sleep Center - Community General Hospital
Syracuse, New York, United States
Duke University Medical Center
Durham, North Carolina, United States
Raleigh Neurology Associates
Raleigh, North Carolina, United States
Central Carolina Neurology & Sleep
Salisbury, North Carolina, United States
CSC Research -- Grove City Sleep Diagnostic Center
Grove City, Ohio, United States
Southwest Cleveland Sleep Center
Middleburg Heights, Ohio, United States
Lynn Health Science Institute
Oklahoma City, Oklahoma, United States
Clinical Pharmaceutical Trials, Inc.
Tulsa, Oklahoma, United States
Rhode Island Hospital - Division of Pulmonary, Sleep and Critical Care Medicine
Providence, Rhode Island, United States
Miriam Hospital
Providence, Rhode Island, United States
Charleston Pulmonary Associates PA
Charleston, South Carolina, United States
Low Country Lung and Critical Care PA
Charleston, South Carolina, United States
Palmetto Baptist Medical Center Sleep Disorders Center
Columbia, South Carolina, United States
Charleston Pulmonary Associates PA
Mt. Pleasant, South Carolina, United States
Sleep Medicine Assoc PLLC -- Summit Medical Center
Hermitage, Tennessee, United States
The Houston Sleep Center
Houston, Texas, United States
Sleep Medicine Associates of Texas
Plano, Texas, United States
Sleep Disorders Center -- Eastern Virginia Medical School -- Sentara General Hospital
Norfolk, Virginia, United States
VCU Health System MCV Hospitals - Sleep Disorders Center
Richmond, Virginia, United States
Swedish Sleep Medicine Institute
Seattle, Washington, United States
Canadian Sleep Institute
Calgary, Alberta, Canada
Vancouver Hospital -- Sleep Disorders Clinic
Vancouver, British Columbia, Canada
Saint John Regional Hospital -- Somnology Program
Saint John, New Brunswick, Canada
The Ottawa Hospital Sleep Centre -- Ottawa Hospital -- Civic Campus -- Sleep Laboratory
Ottawa, Ontario, Canada
The Sleep Disorders Clinic of the Centre for Sleep and Chronobiology
Toronto, Ontario, Canada
Brain & Sleep Diagnostic Center
Toronto, Ontario, Canada
Sleep Disorder Centre -- Hopital du Sacre-Coeur
Montreal, Quebec, Canada
Neurologische Poliklinik - Universitats Spital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep. 2002 Feb 1;25(1):42-9.
Scrima L, Hartman PG, Johnson FH Jr, Thomas EE, Hiller FC. The effects of gamma-hydroxybutyrate on the sleep of narcolepsy patients: a double-blind study. Sleep. 1990 Dec;13(6):479-90. doi: 10.1093/sleep/13.6.479.
Lammers GJ, Arends J, Declerck AC, Ferrari MD, Schouwink G, Troost J. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep. 1993 Apr;16(3):216-20. doi: 10.1093/sleep/16.3.216.
A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep. 2003 Feb 1;26(1):31-5.
Husain AM, Bujanover S, Ryan R, Scheckner B, Black J, Profant J. Incidence and duration of common, early-onset adverse events occurring during 2 randomized, placebo-controlled, phase 3 studies of sodium oxybate in participants with narcolepsy. J Clin Sleep Med. 2020 Sep 15;16(9):1469-1474. doi: 10.5664/jcsm.8530.
Roth T, Dauvilliers Y, Guinta D, Alvarez-Horine S, Dynin E, Black J. Effect of sodium oxybate on disrupted nighttime sleep in patients with narcolepsy. J Sleep Res. 2017 Aug;26(4):407-414. doi: 10.1111/jsr.12468. Epub 2016 Nov 3.
Bogan R, Swick T, Mamelak M, Kovacevic-Ristanovic R, Lai C, Black J, Villa KF, Montplaisir J. Evaluation of Quality of Life in Patients With Narcolepsy Treated With Sodium Oxybate: Use of the 36-Item Short-Form Health Survey in a Clinical Trial. Neurol Ther. 2016 Dec;5(2):203-213. doi: 10.1007/s40120-016-0053-5. Epub 2016 Oct 24.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OMC-SXB-15
Identifier Type: -
Identifier Source: org_study_id